ARIA Incidence with Kisunla (Donanemab)
Up to 29% of patients on Kisunla develop ARIA (any type), with ARIA-E occurring in approximately 16-24% and ARIA-H in 25-31% of patients, depending on the dosing regimen used. 1
Breakdown by ARIA Type and Dosing Regimen
Dosing Regimen 2 (Recommended Dosage)
- Total ARIA: 29% of patients
- ARIA-E (edema/effusion): 16% of patients
- ARIA-H (hemorrhage): 25% of patients
- Symptomatic ARIA-E: 3% of patients 1
Dosing Regimen 1 (Higher Incidence)
- Total ARIA: 36% of patients
- ARIA-E: 24% of patients
- ARIA-H: 31% of patients
- Symptomatic ARIA-E: 6% of patients 1
The recommended Dosing Regimen 2 was specifically selected because it demonstrates lower ARIA-E rates compared to Dosing Regimen 1, making it the safer option for clinical use 1.
Clinical Context from Guidelines
The 2025 ACR Appropriateness Criteria confirms these rates, noting that ARIA-E was detected in up to 26.7% of patients undergoing therapy with donanemab in the TRAILBLAZER-ALZ phase 2 and phase 3 trials 2. This aligns closely with the FDA label data, providing consistent evidence across sources.
For comparison, ARIA-E rates with other anti-amyloid monoclonal antibodies are:
- Aducanumab: 35-36%
- Lecanemab: 12.6% 2
Risk Stratification by ApoE ε4 Status
ARIA risk varies substantially based on ApoE ε4 genotype 1:
Study 1 (Dosing Regimen 1) - 18 months:
- ApoE ε4 homozygotes (ε4/ε4): 55% developed ARIA
- Symptomatic ARIA-E: 8%
- Serious ARIA: 3%
- ApoE ε4 heterozygotes: 36% developed ARIA
- Symptomatic ARIA-E: 7%
- Serious ARIA: 2%
- ApoE ε4 noncarriers: 25% developed ARIA
- Symptomatic ARIA-E: 4%
- Serious ARIA: 1%
Study 2 (Dosing Regimen 2) - 12 months:
- ApoE ε4 homozygotes: 0% symptomatic ARIA-E (limited sample size)
- ApoE ε4 heterozygotes: 4% symptomatic ARIA-E
- ApoE ε4 noncarriers: 3% symptomatic ARIA-E 1
ApoE ε4 homozygotes represent approximately 15-17% of Alzheimer's disease patients but carry the highest ARIA risk. Testing for ApoE ε4 status should be performed prior to treatment initiation to inform risk assessment, though treatment can proceed without testing if patients accept the inability to stratify their individual risk 1.
Timing and Severity
ARIA-E typically occurs early in treatment: In 58.3% of donanemab-treated participants who developed ARIA-E, the first event occurred by the third infusion (approximately month 3) 3. This early timing pattern underscores the critical importance of intensive MRI monitoring during the initial treatment phase.
Most ARIA-E is mild to moderate in severity, but serious ARIA-E occurred in 1.5% of patients in placebo-controlled trials 1. Approximately 85% of patients with symptomatic ARIA-E had resolution of clinical symptoms in Study 1, though this decreased to 67% at 12 months in Study 2 1.
Additional Risk Factors Beyond ApoE ε4
Independent risk factors for ARIA-E include 3:
- Baseline microhemorrhages (≥2 increases risk)
- Cortical superficial siderosis (≥1 area increases risk)
- Higher baseline amyloid plaque burden
- Elevated mean arterial pressure
- Decreased risk with antihypertensive use
Critical Safety Considerations
Intracerebral hemorrhage >1 cm occurred in 0.5-1% of patients treated with Kisunla 1. Fatal events of intracerebral hemorrhage have been observed, and three deaths in clinical trials were considered treatment-related 4.
Mandatory MRI monitoring is required with sequences including DWI, T2 FLAIR, and T2* GRE or SWI to detect ARIA, as it cannot be reliably detected on CT 2, 1. Regular monitoring should occur before specified infusions, with additional imaging if clinical symptoms develop (headache, confusion, visual changes, dizziness, nausea, gait difficulty, or focal neurologic deficits) 2, 1.